000278909 001__ 278909
000278909 005__ 20250604100731.0
000278909 0247_ $$2doi$$a10.1038/s41598-025-98338-9
000278909 0247_ $$2pmid$$apmid:40415101
000278909 0247_ $$2pmc$$apmc:PMC12104337
000278909 037__ $$aDZNE-2025-00635
000278909 041__ $$aEnglish
000278909 082__ $$a600
000278909 1001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris-Stephan$$b0$$eFirst author$$udzne
000278909 245__ $$aMultimodal and longitudinal characterization of distinct tau and atrophy clusters in Alzheimer's disease spectrum.
000278909 260__ $$a[London]$$bSpringer Nature$$c2025
000278909 3367_ $$2DRIVER$$aarticle
000278909 3367_ $$2DataCite$$aOutput Types/Journal article
000278909 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748603699_29958
000278909 3367_ $$2BibTeX$$aARTICLE
000278909 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278909 3367_ $$00$$2EndNote$$aJournal Article
000278909 520__ $$aNeuropathological and neuroimaging studies have identified several (endo-)phenotypes of Alzheimer's disease (AD), suggesting a substantial heterogeneity in cerebral atrophy and tau spreading patterns. We included in our study a total of 320 participants, including healthy controls (N = 154) and patients across the AD spectrum (N = 166). We identified clusters of cerebral atrophy and tau PET uptake using a data-driven and similarity-based clustering approach, aiming to examine regional abnormality patterns in both modalities and differences in the clinical, cognitive, and biomarker characteristics among derived clusters. Abnormality patterns in tau PET and T1-weighted MRI within the same individuals revealed four distinct clusters for each imaging modality as surrogate markers of tau and neurodegeneration, respectively. The tau PET and atrophy clusters mainly showed substantial differences in their clustering allocations. While having the most severe biomarkers burden, the left temporal tau and diffuse atrophy clusters revealed the fastest clinical progression and steepest increase in tau PET uptake. Moreover, the diffuse atrophy cluster showed the fastest cortical volume loss, followed by the limbic-predominant atrophy cluster. Our results suggest characteristic differences between tau PET and atrophy clusters, especially for tau PET clusters, revealing more pronounced differences in cognitive profiles and disease biomarker trajectories than atrophy clusters.
000278909 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278909 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x1
000278909 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278909 650_7 $$2Other$$aCognitive decline and dementia
000278909 650_7 $$2Other$$aPhenotypical heterogeneity
000278909 650_7 $$2Other$$aPrecision medicine
000278909 650_7 $$2Other$$aSimilarity-based Louvain clustering
000278909 650_7 $$2NLM Chemicals$$atau Proteins
000278909 650_7 $$2NLM Chemicals$$aBiomarkers
000278909 650_2 $$2MeSH$$aHumans
000278909 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000278909 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000278909 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000278909 650_2 $$2MeSH$$atau Proteins: metabolism
000278909 650_2 $$2MeSH$$aMale
000278909 650_2 $$2MeSH$$aFemale
000278909 650_2 $$2MeSH$$aAtrophy
000278909 650_2 $$2MeSH$$aAged
000278909 650_2 $$2MeSH$$aPositron-Emission Tomography
000278909 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000278909 650_2 $$2MeSH$$aBiomarkers: metabolism
000278909 650_2 $$2MeSH$$aLongitudinal Studies
000278909 650_2 $$2MeSH$$aMiddle Aged
000278909 650_2 $$2MeSH$$aNeuroimaging
000278909 650_2 $$2MeSH$$aDisease Progression
000278909 650_2 $$2MeSH$$aBrain: pathology
000278909 650_2 $$2MeSH$$aBrain: diagnostic imaging
000278909 650_2 $$2MeSH$$aBrain: metabolism
000278909 650_2 $$2MeSH$$aAged, 80 and over
000278909 650_2 $$2MeSH$$aCluster Analysis
000278909 7001_ $$0P:(DE-2719)9002917$$aErsözlü, Ersin$$b1$$eFirst author$$udzne
000278909 7001_ $$aLuedecke, Dorothea$$b2
000278909 7001_ $$aFranzmeier, Nicolai$$b3
000278909 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b4$$eLast author$$udzne
000278909 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-025-98338-9$$gVol. 15, no. 1, p. 18142$$n1$$p18142$$tScientific reports$$v15$$x2045-2322$$y2025
000278909 8564_ $$uhttps://pub.dzne.de/record/278909/files/DZNE-2025-00635.pdf$$yOpenAccess
000278909 8564_ $$uhttps://pub.dzne.de/record/278909/files/DZNE-2025-00635%20SUP.docx
000278909 8564_ $$uhttps://pub.dzne.de/record/278909/files/DZNE-2025-00635.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278909 909CO $$ooai:pub.dzne.de:278909$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000278909 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001808$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000278909 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002917$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000278909 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000278909 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278909 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x1
000278909 9141_ $$y2025
000278909 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-29T15:28:26Z
000278909 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-29T15:28:26Z
000278909 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278909 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2024-12-18
000278909 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000278909 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278909 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000278909 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000278909 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x1
000278909 9201_ $$0I:(DE-2719)1810002$$kAG Dirnagl$$lVascular Pathology$$x2
000278909 980__ $$ajournal
000278909 980__ $$aVDB
000278909 980__ $$aUNRESTRICTED
000278909 980__ $$aI:(DE-2719)5000022
000278909 980__ $$aI:(DE-2719)1110008
000278909 980__ $$aI:(DE-2719)1810002
000278909 9801_ $$aFullTexts